New vaccine boosts CAR-T power against bone marrow cancer
NCT ID NCT07377435
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether adding a personalized cancer vaccine (made from a patient's own immune cells and tumor cells) to standard CAR-T cell therapy can safely improve outcomes for people with multiple myeloma that has returned or stopped responding to treatment. About 25 adults will receive the vaccine plus a growth factor alongside their CAR-T therapy. The study focuses on safety first, but also looks at how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized cancer vaccine (DC/MM fusion vaccine) plus growth factor (GM-CSF)
- What this could lead to
- If it works, this combination could improve the effectiveness of CAR-T therapy and help more people with multiple myeloma achieve long-term remission.
- What could go wrong
- This is a very early Phase 1 trial with only 25 people, so safety and effectiveness are still unknown. There are risks of serious side effects like cytokine release syndrome and nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered donor cells could outsmart relapsed myeloma
- Talking about the end: could guided conversations reduce futile cancer treatments?